Compare BioNano Genomics Inc (BNGO) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Logitech International SA — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Logitech International SA trades at $101 (market cap $14.96B). The key difference: Logitech International SA is far larger — about 1095.2× BioNano Genomics Inc's market cap, and Logitech International SA pays a 1.64% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | LOGI | |
|---|---|---|
Market Cap | $13.66M | $14.96B |
Sector | Health | Technology |
52-Week High | $4.92 | $126.69 |
52-Week Low | $1.06 | $85.84 |
Enterprise Value | $16.26M | $13.30B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Logitech (LOGI) trades at $104.87, down 1.37% on the day, with a neutral technical signal and mixed analyst sentiment. Recent Q1 2027 earnings beat estimates with EPS of $1.85 versus $1.26 expected, driven by tariff refunds and premium demand, though a key supplier shutdown clouds near-term outlook. Fundamentals show strong profitability with a 16.28% net margin and 35.29% ROE, while valuation metrics like a P/E of 19.03 appear reasonable. The stock faces resistance near $109, with support at $104.
The outlook is cautiously optimistic given solid earnings momentum and margin expansion, but supply chain disruptions pose a near-term risk. Upside to the $109.75 consensus price target offers potential, though investor sentiment is divided amid operational uncertainties. Key risks include supplier dependency and competitive pressures in the tech peripherals market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
